No patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.The device remains implanted, and no clinical images enabling direct assessment of product performance were returned for evaluation.A review of manufacturing records verified that the lot involved in this complaint met all pre-release specifications.No allegation of device malfunction, such as stent collapse or structural deformation was indicated with respect to device performance.Heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
On (b)(6) 2022 this patient underwent an endovascular treatment of a graft occlusion (thrombosis) with a gore® viabahn® endoprosthesis with propaten bioactive surface (vsx).Reportedly, the lesion type is a restenosis and the patient has had 4 prior known interventional procedures.The pre-procedure stenosis is reported to be a total occlusion and the target lesion is located within the stent graft.The location of the current prosthetic graft being treated is on the left upper arm (axillary vein).On (b)(6) 2022 an adverse event termed thrombosis of avg was discovered and an endovascular surgical intervention was performed on the same day (b)(6) 2022.The patient received an antiplatelet during the procedure.Reportedly, the patency of the vsx was restored at the end of the procedure and patient recovered without any sequelae and was discharged on (b)(6) 2022.
|